Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 6, 2006, Pages 678-681

  Haddad, Robert ^a,b   Tishler, Roy ^a   Wirth, Lori ^a   Norris, Charles M ^c   Goguen, Laura ^c   Sullivan, Christopher ^d   O'Donnell, Lindsay ^b   Li, Yi ^a   Posner, Marshall ^a  

^a Department of Medical Oncology ^*  (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 33745228428     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.6.678     Document Type: Article

References (23)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress: head and neck cancer. N Engl J Med. 2001;345:1890-1900.
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. N Engl J Med. 2003;349:2091-2098.
3. Domenge C, Hill C, Lefebvre J, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer. 2000;83:1594-1598.
4. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer. Cancer. 1985;55:1123-1128.
5. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. J Natl Cancer Inst. 1996;88:890-898.
6. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1689.
7. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo. J Natl Cancer Inst. 1994;86:265-272.
8. Catimel G, Verwij J, Hanauske A, et al; EORTC Early Clinical Trials Group. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994;5:533-537.
9. Dreyfuss AI, Clark J, Norris C, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672-1678.
10. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003;97:412-418.
11. Haddad R, Tishler RB, Norris CM, et al. TPF-based induction chemotherapy for head and neck cancer and the case for sequential, combined modality treatment. Oncologist. 2003;8:35-44.
12. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096-1104.
13. Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984;54:811-814.
14. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol. 1994;12:1592-1599.
15. Jacobs C, Goffinet D, Goffinet L, Kohler M, Fee W. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer: a report from the Northern California Oncology Group. Cancer. 1987;60:1178-1183.
16. Tishler RB, Norris CM Jr, Colevas AD, et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 2002;95:1472-1481.
17. Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003;30(suppl 18):84-88.
18. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645.
19. Vermorken JB, Remenar E, Van Herpen C, et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971) [abstract]. J Clin Oncol. 2004:22(suppl):5508.
20. Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004;31:778-785.
21. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003;21:320-326.
22. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania phase II trial. J Clin Oncol. 2002;20:3964-3971.
23. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006;24:593-598.